IPSEN (OTCMKTS:IPSEY) Sets New 52-Week High – Still a Buy?

Shares of IPSEN (OTCMKTS:IPSEY) hit a new 52-week high on Wednesday . The company traded as high as $40.97 and last traded at $40.97, with a volume of 230 shares trading hands. The stock had previously closed at $40.86.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on the stock. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating on shares of IPSEN in a research report on Monday, November 3rd. BNP Paribas Exane downgraded shares of IPSEN to an “underperform” rating in a report on Wednesday, November 26th. Finally, UBS Group cut IPSEN from a “strong-buy” rating to a “hold” rating in a report on Thursday, January 8th. One research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Hold”.

IPSEN Stock Up 0.6%

The firm’s fifty day simple moving average is $36.74 and its two-hundred day simple moving average is $34.78.

IPSEN Company Profile

Ipsen is a global biopharmaceutical company headquartered in Boulogne-Billancourt, France. Founded in 1929, the company focuses on specialty care areas including oncology, neuroscience and rare diseases. Ipsen develops, manufactures and commercializes innovative medicines that address critical unmet medical needs, offering a diverse portfolio of therapies for both adult and pediatric patient populations.

The company’s oncology franchise includes treatments for prostate, renal and hepatocellular carcinomas, with key products such as Cabometyx (cabozantinib) and Decapeptyl (triptorelin).